U.S. markets close in 3 hours 24 minutes
  • S&P 500

    4,455.54
    +59.90 (+1.36%)
     
  • Dow 30

    34,815.43
    +557.11 (+1.63%)
     
  • Nasdaq

    15,043.06
    +146.22 (+0.98%)
     
  • Russell 2000

    2,252.65
    +34.09 (+1.54%)
     
  • Crude Oil

    73.18
    +0.95 (+1.32%)
     
  • Gold

    1,751.10
    -27.70 (-1.56%)
     
  • Silver

    22.70
    -0.21 (-0.90%)
     
  • EUR/USD

    1.1745
    +0.0049 (+0.42%)
     
  • 10-Yr Bond

    1.4040
    +0.0680 (+5.09%)
     
  • GBP/USD

    1.3749
    +0.0129 (+0.95%)
     
  • USD/JPY

    110.1490
    +0.3710 (+0.34%)
     
  • BTC-USD

    43,855.91
    +608.76 (+1.41%)
     
  • CMC Crypto 200

    1,101.67
    -7.25 (-0.65%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LOS ANGELES, CA / ACCESSWIRE / August 17, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ('Athira' or 'the Company') (NASDAQ:ATHA) for violations of the federal securities laws.

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the 'IPO'), or between September 18, 2020 and June 17, 2021, both dates inclusive (the 'Class Period'), are encouraged to contact the firm before August 24, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Research performed by Athira CEO and President Leen Kawas was tainted by scientific misconduct. Kawas allegedly engaged in the manipulation of key data in the research through the manipulation of Western blot images. The tainted research was of critical importance to the Company's efforts to develop treatments for Alzheimer's. The Company's research and development efforts were based on invalid data. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Athira, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/660226/FINAL-DEADLINE-IMMINENT-The-Schall-Law-Firm-Announces-the-Filing-of-a-Class-Action-Lawsuit-Against-Athira-Pharma-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-250000-to-Contact-the-Firm